Church & Dwight (CHD): What to Expect from Q1 2026 Earnings
Key Takeaways
- Analysts expect Q1 2026 EPS (earnings per share) of $0.93, reflecting 2.2% year-over-year growth.
- Consensus revenue estimate stands at $1.47 billion, approximately flat compared to Q1 2025's $1.467 billion.
- Church & Dwight has beaten EPS estimates in the trailing four quarters by an average of 6.6%.
- Full-year 2026 adjusted EPS guidance targets 5% to 8% growth over 2025.
- Investors will watch organic sales growth, gross margins, and updates on key categories like personal care and household products.
- Recent Q4 2025 results showed 3.9% net sales growth, supporting momentum into the new year.
Earnings Context and Why It Matters
Church & Dwight (CHD), a leading consumer staples company known for brands like Arm & Hammer, OxiClean, and Trojan, faces a pivotal Q1 2026 earnings report amid shifting consumer dynamics. The company has navigated volume pressures in mature categories through pricing actions and innovation, delivering consistent profitability. With shares trading around $95 after peaking near $106 earlier this year, this report will gauge early progress toward full-year goals. From what I see, it offers key insights for investors into demand resilience, margin trends, and the impact of recent acquisitions like Touchland hand sanitizer, especially as peers report mixed consumer spending signals.
Earnings Expectations
Wall Street anticipates Q1 2026 revenue of $1.47 billion for CHD, implying a slight dip or flat performance versus Q1 2025's $1.467 billion, driven by potential softness in volumes offset by pricing. EPS consensus is $0.93, up from $0.91 adjusted in the year-ago quarter. This reflects expectations of steady gross margins around 44-45%, bolstered by supply chain efficiencies.
Key metrics in focus include organic sales growth, projected near flat after Q4 2025's 0.7% rise, and performance across segments: Consumer Domestic (76% of sales), Consumer International, and Specialty Products Division (SPD). Historically, CHD has posted strong EPS beats, with Q1 2025 adjusted EPS of $0.91 topping estimates despite a sales miss. Stock reactions have been muted to positive on beats, averaging +1-2% post-earnings over recent quarters. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into Q1 earnings, sentiment leans cautiously optimistic for CHD, buoyed by the company's earnings beat streak and full-year guidance reaffirmation in January. Shares have declined about 10% from February highs amid broader consumer staples rotation, but analysts maintain a consensus "Buy" rating with a $102 target. Risks include weaker-than-expected volumes from economic headwinds or competitive pressures in laundry and oral care. In my view, a beat could spark a rebound, while an in-line or miss on sales might pressure the stock further. I’m watching Tickeron’s AI Daily Buy/Sell Signals for any shifts in real-time sentiment around earnings.
Tickeron’s AI Screener
One tool I rely on regularly in my research is Tickeron’s AI Screener, an AI-powered stock and ETF discovery tool that helps me filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows scanning thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics—making it far more efficient than manual screening for identifying trade ideas, trending stocks, breakout candidates, and market opportunities. I used it here to evaluate CHD against peers, and it’s become a staple in my process.
Forward Outlook and Key Factors to Monitor
Following Q1 results, investors should track management's commentary on full-year 2026 guidance for CHD, which projects adjusted EPS growth of 5% to 8% over 2025's levels. This outlook hinges on 2-4% organic sales growth, gross margin expansion from productivity gains, and contributions from high-growth areas like hand sanitizers and pet care.
Upcoming catalysts include Q2 volume trends amid easing inflation, progress on innovation pipelines such as new Arm & Hammer formulations, and international expansion. Margin pressures from input costs or marketing investments will be scrutinized, alongside SPD performance in animal productivity and food protection.
One thing that stands out is how broader industry dynamics, including consumer health spending and retail partner inventories, remain critical. CHD's focus on everyday essentials positions it defensively, but sustained demand signals in core categories will be key to achieving guidance midpoints.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CHD sees MACD Histogram crosses below signal line
CHD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHD as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CHD broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CHD moved above its 50-day moving average on August 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHD advanced for three days, in of 343 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 231 cases where CHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.391) is normal, around the industry mean (23.642). P/E Ratio (31.667) is within average values for comparable stocks, (56.718). Projected Growth (PEG Ratio) (2.995) is also within normal values, averaging (2.919). CHD has a moderately low Dividend Yield (0.012) as compared to the industry average of (0.034). P/S Ratio (3.804) is also within normal values, averaging (2.707).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of sodium bicarbonate and sodium bicarbonate based products
Industry HouseholdPersonalCare
Advertisement